Vivlion licenses CRISPR tech from ERS Genomics

By The Science Advisory Board staff writers

December 1, 2020 -- Vivlion has signed a nonexclusive license agreement to access ERS Genomics' CRISPR/Cas9 patent portfolio to enhance Vivlion's gene editing reagents and screening services.

Vivlioin, a German startup focused on next-generation CRISPR/Cas guide RNA (gRNA) libraries and screening services, holds an exclusive license to Goethe University of Frankfurt's proprietary 3Cs technology for the production of next-generation 3Cs CRISPR/Cas gRNA libraries.

The technology enables single and dual-combinatorial CRISPR/Cas libraries to be produced without compromising quality. This new license will enable Vivlion to offer both research and development reagents and screening services to its customers worldwide.

Financial details of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.